Shanghai MicuRx Pharmaceutical Co., Ltd.SSE: 688373

Announcement on Convening the Q1 2025 Performance Briefing

May 20, 2025 · Issued by Shanghai MicuRx Pharmaceutical Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · May 20, 2025

On 6ix: 6ix.com/news/announcement-on-convening-the-q1-2025-performance-briefing-61

Announcement on Convening the Q1 2025 Performance Briefing

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

6ix hasn’t read this filing yet.

Shanghai MicuRx Pharmaceutical Co., Ltd. on 6ix

Earlier from Shanghai MicuRx Pharmaceutical

Announcement on the Resignation of Independent DirectorsMay 13, 2025
Report for Q1 2025Apr 24, 2025
Announcement on Attending the 2024 SSE STAR Market Innovative Drug Industry Collective Performance BriefingApr 15, 2025
MicuRx: 15 Clinical and Preclinical Research Studies to be Presented at ESCMID Global 2025Apr 8, 2025
Announcement on Vesting Results in the 1st Vesting Period of Initial Grant in 2023 Restricted Stock Incentive Plan and Shares ListingMar 21, 2025

Later from Shanghai MicuRx Pharmaceutical

Announcement on the Voluntary Disclosure of Acceptance of the New Drug Application for the Marketing Authorization of Contezolid Acefosamil Sodium for InjectionMay 22, 2025
Announcement on Resolution of the 2024 Annual General MeetingJun 6, 2025
Announcement on Reply to Letter of Supervision and Inquiry on Information Disclosure of 2024 Annual ReportJun 28, 2025
Notice on Convening the 1st Extraordinary General Meeting in 2025Jul 2, 2025
Announcement on Change of Sponsor RepresentativeJul 16, 2025

All Shanghai MicuRx Pharmaceutical news releases

Follow Shanghai MicuRx Pharmaceutical into a list and get an email when it puts out news.

Follow Shanghai MicuRx Pharmaceutical